TSN: The Stock Network

Li-FT Power has dual listed on the ASX with the ticker code of LFT. Assuming shareholder and court approvals are forthcoming, Li-FT Power will acquire all shares and options in ASX- listed Winsome Resources post the IPO, after which Winsome Resources will delist from the ASX. Post completion of the Winsome Resources’ acquisition, Li-FT Power will focus on the unique opportunity available to de-risk and accelerate the development of its emerging Quebec, Canada-based Galinée Lithium Project, and the immediately adjacent Adina Lithium Project currently owned by Winsome Resources. Media: The Stock Network, @LelSmits @Li_FTPower $LFT

Impact Minerals (ASX:IPT) has announced further high-grade gold and silver results from the Commonwealth–Silica Hill Project in New South Wales. 🛘 The project currently hosts JORC Inferred Mineral Resources totalling 88,800 ounces of gold and 3.3 million ounces of silver. 🪓 Broad mineralised zones confirmed between Commonwealth and Commonwealth South, supporting continuity across the system. ⚒️ High-grade gold intersected at Commonwealth South, including: 🔹7.1m @ 8.4 g/t gold, 42 g/t silver, 1.5% zinc and 0.7% lead 🔹Including 3.1m @ 18.6 g/t gold and 76 g/t silver 🔎Significant breakthrough at Silica Hill, with drilling returning: 🔹3.4m @ 4.1 g/t gold and 2,947 g/t silver 🔹Including bonanza-grade mineralisation of 0.5m @ 27 g/t gold and 20,603 g/t silver "We have had a major breakthrough in extending the mineralised system at Silica Hill with a very high grade intercept of 0.5 metres at 27 g/t gold and 2% silver in an area that is open in all directions, as well as extending the resource at Commonwealth and Commonwealth South." Dr. Mike Jones, Impact’s Managing Director ASX announcement ⚡ cdn-api.markitdigital.com/apiman-gateway… @ImpactMinerals $IPT

@Decidr_ai Industries (ASX: DAI) has partnered with Australian sovereign AI cloud provider SouthernCrossAI (SCX.ai) to establish the first Australian node in its multi-jurisdiction sovereign inference architecture, supporting the rollout of DecidrOS and advancing the Company’s Knowledge Security strategy for enterprise and government customers. 🤖 Decidr AI Industries expands sovereign AI infrastructure strategy, with SCX.ai appointed as the Company’s first sovereign inference partner in Australia, supporting deployment of DecidrOS for enterprise and government customers requiring Australian-based AI infrastructure and data residency. 🔐 Strengthening Knowledge Security capabilities, with the partnership enabling organisations to capture, fine-tune and continuously update proprietary AI models on infrastructure operating entirely within Australian jurisdiction, aligning with growing regulatory and procurement requirements across financial services, healthcare and government sectors. 🌏 Building multi-jurisdiction AI architecture, with SCX.ai forming the Australian node in Decidr AI Industries’ broader sovereign inference network spanning Europe, Asia-Pacific and the United States, while supporting future rollout plans for additional Australian and regional nodes. Decidr AI Industries Executive Chairman David Brudenell commented: “The agentic economy runs on inference, and inference runs on infrastructure. Partnering with SCX.ai gives Decidr customers a domestic, high-performance foundation on which to deploy their own fine-tuned models with confidence. It is the Australian node in a broader multi-jurisdiction architecture we are building to meet enterprise demand for sovereign AI globally.” ASX Announcement link ⚡ cdn-api.markitdigital.com/apiman-gateway…

What separates businesses that become long-term Wealth Winners® from those where growth becomes a Capital Killer™? In his newly released book, Andrew Coleman shares why so many companies struggle to scale beyond the $10 million mark and what it really takes to build sustainable, compounding growth. From chasing growth to creating enduring value, this book breaks down the mindset, strategy and execution behind businesses that stand the test of time. Book link is here ⚡ amazon.com.au/Wealth-Winners…

Mayne Pharma Group (ASX: MYX) has been awarded more than $13.27 million in legal costs following its successful court proceedings against Cosette Pharmaceuticals. This legal disputation was linked to the earlier termination of a Scheme Implementation Deed signed in February 2025. ⚖️ Court awards Mayne Pharma legal costs, with the Supreme Court of New South Wales determining that Cosette Pharmaceuticals must pay around $13.27 million plus interest following the dismissal of Cosette Pharmaceuticals’ claims in the 2025 termination proceedings. 📑 The proceedings stemmed from a terminated acquisition agreement, with Mayne Pharma commencing legal action in June 2025 after Cosette Pharmaceuticals purported to terminate the Scheme Implementation Deed entered into by both parties in February 2025. 💰 Additional payment orders are expected, with the Court anticipated to shortly formalise orders relating to interest payments, payment timeframes and Mayne Pharma’s additional legal costs associated with the cost application proceedings. Mayne Pharma noted in the announcement that the Court had previously delivered judgment in favour of the Company in October 2025, dismissing all of Cosette Pharmaceuticals’ claims and making an adverse costs order requiring the latter company to pay Mayne Pharma’s legal costs associated with the proceedings. ASX Announcement link ⚡ cdn-api.markitdigital.com/apiman-gateway…

Australia’s central bank (RBA) has been hiking interest rates to fight inflation and higher rates are doing their job, maybe a little too well. Businesses are cutting back, hiring is slowing and jobs are disappearing. Australia's unemployment rate just jumped to 4.5%, the highest level since late 2021, according to ABS figures released last week. This is what economists call the lag effect of rate hikes: you raise rates today, and businesses feel it six to twelve months later. Right now, they're feeling it. The job losses are the proof. For everyday Australians, this is real. Variable mortgage holders are already squeezed. Now their job security is wobbling too. The RBA will now be caught between a rock and a hard place when it meets next month: keep hiking and risk a real jobs crisis, or pause and risk inflation increasing #fintok #moneytok #jobs #economy #Australia

Guzman Y Gomez's (ASX:GYG) share price jumped after the burrito making company said its closing up its US business. GYG says it will immediately exit the US market and close its Chicago restaurants after deciding the business would take far more time and capital to succeed than expected. The company said US sales momentum was too weak to justify ongoing investment, this despite progress on brand awareness and customer experience. GYG also upgraded its earnings guidance for its Australian business, showing it’s focusing on its strongest market instead of burning cash overseas. Even though the stock remains down around 30% since listing on the ASX its shares went up following the US exit news. Showing investor may want expansion, but only when it delivers strong returns. #food #US #stocks #fintok #eat

This week NVIDIA Corp (NASDAQ:NVDA) posted record revenue of $81.6 billion for the first quarter, beating market expectations. On top of that, the company increased its dividend and raised its guidance for the next quarter. Nvidia’s profits are soaring because tech giants like @Google, @Microsoft, @amazon and Meta have no choice but to keep buying its chips. AI infrastructure runs on @nvidia. Think of it like electricity in the early 1900s. If you wanted to make money back then, you didn't invest in the lightbulb, you invested in the power grid. Every company racing to build AI has to buy Nvidia hardware to even enter the race. Nvidia didn't just have a strong quarter. It proved that AI has crossed the line from hype to infrastructure and if you are in a super fund or invest in an ETF, you likely own a slice of it. #moneytok #fintok #AI #NVIDIA #tech $NVDA @AIatMeta

Tartana Minerals (ASX:TAT) is building a diversified Far North Queensland copper-gold and critical minerals business and has just launched its largest drilling campaign to date. The Company stacked 50,000 tonnes of mineralised material on its heap leach pad, advanced upgrades to its copper sulphate plant and acquired a new drilling rig for a 21,000m exploration program. Managing Director Dr Stephen Bartrop joins The Stock Network’s @LelSmits to discuss production growth and exploration plans for 2026. 🪓 Copper production ramp-up 🛘 Building a regional copper-gold platform ⚒️ Expanding exposure to critical minerals Watch the full interview ⚡youtu.be/MozrCUcxqTI @tartanaminerals $TAT

Dateline Resources (ASX: DTR, OTCQB: DTREF, FSE: YE1) has appointed Alvarez & Marsal to manage the construction and development of the Colosseum Gold Mine in California. ⚒️ Appointed Alvarez & Marsal as Construction Manager and integrated owner’s team for the Colosseum Gold Mine 🪓 A&M brings experience from 120+ major mining and infrastructure projects globally 🤝 Leadership team headed by Pierre Légaré, Managing Director and Head of Infrastructure & Capital Projects in Canada "Dateline intends to run a simple contracting strategy, through hard dollar commercial contracts wherever possible. A&M has an excellent reputation for on time, on budget project delivery by carefully managing budgets and timetables." Simon Slesarewich, Dateline’s Chief Operating Officer "We commenced discussions about Colosseum at the beginning of the year and have closely followed the progress of the Bankable Feasibility Study. We have reviewed and endorse Dateline’s simple and effective execution strategy for the delivery of Colosseum." Pierre Légaré, Alvarez & Marsal’s Managing Director ASX announcement ⚡ cdn-api.markitdigital.com/apiman-gateway… @Dateline_DTR $DTR @alvarezmarsal

Teaminvest Private Group (ASX:TIP) has entered into a binding term sheet to acquire the Intelligent Investor business, including management rights to its four Intelligent Investor Exchange Traded Funds, from InvestSMART Group (ASX:INV). Teaminvest Private Group Chief Executive Officer, Andrew Coleman, joins @LelSmits from The Stock Network to discuss the strategic rationale behind the proposed acquisition, the future of the Intelligent Investor brand and TIP’s long-term growth strategy. 📊 Strategic rationale behind the acquisition 🐚 Expanding retail distribution and scale 🏢 Building the future of Intelligent Investor Watch the full interview ⚡ youtu.be/H9LxRrQ3cIE @TIPGroup_Ltd $TIP @value_investing @InvestSMART_AU

Anteris Technologies (ASX & NASDAQ:AVR) has announced the first U.S. patients have been enrolled and successfully treated in the global pivotal PARADIGM Trial evaluating the DurAVR® Transcatheter Heart Valve. This marks a significant milestone in the Company’s clinical development pathway for severe calcific aortic stenosis. 💊 First U.S. patients enrolled and treated in pivotal PARADIGM Trial, which is evaluating Anteris Technologies’ DurAVR® Transcatheter Heart Valve for severe calcific aortic stenosis, and is being undertaken at Montefiore Medical Center in New York. 🩺 Expanding global clinical trial momentum, with the PARADIGM Trial designed as a head-to-head study comparing the DurAVR® THV against commercially available transcatheter aortic valve replacement devices across approximately 1,000 patients globally. 📈 Advancing evidence generation for future patient care, with the trial assessing not only safety and clinical outcomes, but also the impact of blood flow patterns on left ventricular recovery, as U.S. study sites come online to expand recruitment capability. Anteris Technologies Vice Chairman and Chief Executive Officer Wayne Paterson commented: “Following CMS approval, the Anteris team and our physician partners worked closely together to achieve first patient enrolments within the week. This marks a major milestone for the PARADIGM Trial as our US study sites come on line and expand recruitment capability.” ASX announcement⚡ cdn-api.markitdigital.com/apiman-gateway… @AnterisTech $AVR

SkinKandy has listed on the ASX with the ticker code of SK1. The company is the leading specialist piercing retailer in both Australia and New Zealand. Its business is anchored by expert piercing services and supported by a curated and comprehensive range of piercing- related fashion jewellery and aftercare products. SkinKandy’s growth strategy will initially be focussed on delivery of increased category offerings, further expansion of its Australia and New Zealand store network, and continued investment in the Company’s digital platforms. Website: skinkandy.com Media: The Stock Network, @LelSmits #skinkandy #SK1

Electro Optic Systems Holdings (ASX:EOS) has announced the completion of the MARSS acquisition. 🛰️ MARSS has established systems and personnel supporting operations across the Middle East, remains committed to protecting critical sites, and continues advancing operational capabilities. “We are pleased to have completed the MARSS acquisition – this is a significant addition to EOS’ capability. In recent months, the MARSS NiDAR platform has been protecting critical assets in the Middle East from drone attacks" Dr. Andreas Schwer, EOS CEO and Managing Director "We are very proud of the MARSS team and the success of the NiDAR Counter-Drone Command and Control platform." Johannes Pinl, MARSS CEO ASX announcement ⚡ cdn-api.markitdigital.com/apiman-gateway… @aussie_eos $EOS

Island Pharmaceuticals (ASX:ILA) has continued to expand its engagement across the US biodefence ecosystem ahead of planned FDA Animal Rule studies for Galidesivir targeting Marburg Virus Disease. Flowing from these efforts, the Company has appointed experienced biodefence executive Mark Herzog as Senior Global Health Security Advisor and has also secured representation on key Medical Countermeasures Coalition (MC2) working groups. 🛡️ US biodefence engagement expanded, with Island Pharmaceuticals appointing Mark Herzog as Senior Global Health Security Advisor, bringing more than 25 years of experience across biodefence, medical countermeasure development and government contracting, including a track record of securing more than US$100 million in government contracts. 🧪 Strategic positioning strengthened ahead of FDA Animal Rule studies, with Island Pharmaceuticals expanding engagement across key US agencies and biodefence stakeholders including the Department of Defense (DoD), the Department of Health & Human Services (HHS), Center for the Biomedical Advanced Research and Development Authority (BARDA) and the Medical Countermeasures Coalition. This work will support the Company’s future regulatory, procurement and Strategic National Stockpile opportunities for Galidesivir. 🌍 Advancing Marburg Virus Disease development pathway, with Island Pharmaceuticals remaining on track to commence planned dose optimisation studies next quarter under the FDA Animal Rule pathway, while continuing collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and participating in MC2 working groups focused on biodefence R&D, procurement and stockpiling policy. Island Pharmaceuticals CEO and Managing Director Dr David Foster commented: “These initiatives represent important steps in Island’s strategy to strengthen our engagement across the US biodefence and global health security ecosystem as we continue advancing Galidesivir under the FDA’s Animal Rule pathway for Marburg Virus Disease. The appointment of Mark Herzog materially enhances Island’s strategic engagement capability through his extensive experience across biodefence policy, medical countermeasure development, government affairs and procurement initiatives. Importantly, his relationships and experience across agencies including the DoD, HHS and BARDA are highly complementary to Island’s ongoing regulatory and clinical development activities. Collectively, these initiatives continue to strengthen Island’s strategic positioning as we move closer toward commencement of our planned Animal Rule studies next quarter and advance Galidesivir toward potential future regulatory, procurement and stockpiling opportunities.” ASX announcement ⚡ cdn-api.markitdigital.com/apiman-gateway… @IslandPharma @ILA

Iconic Australian agribusiness Elders (ASX:ELD) is worth more than $1 billion and runs farm services, sells livestock, manages real estate in rural areas, and provides supplies to Australian farmers. Elders half year results showed revenue grew 32% to A$1.77 billion. Earnings up 33%. Their big acquisition, Delta Agribusiness, is performing well. But, despite saying it's well positioned for the second half, Elders also warned about elevated diesel prices and price volatility in fuel and fertiliser. When the agriculture sector struggles, that flows through to food prices, inflation and every household in the country. #ASX #stocks #food #farms #Australia $ELD

Electro Optic Systems Holdings (ASX:EOS) has completed a A$150 million placement and announced a A$40 million strategic placement. 🛰️ The institutional placement received strong support from both existing and new institutional investors 🔧 Settlement of the new shares is expected on 22 May 2026, with ASX trading expected to commence on 25 May 2026 🎯 The strategic placement includes a commitment from Generation 5 Holding L.L.C, a related entity of Abu Dhabi-based defence provider Calidus L.L.C ASX announcement ⚡ cdn-api.markitdigital.com/apiman-gateway… @aussie_eos $EOS

EBR Systems, Inc. (ASX:EBR) has secured a three-year purchasing agreement with CHRISTUS Health. 🏥 CHRISTUS Health is the ninth-largest hospital network in the United States 🤝 Agreement establishes a purchasing pathway for the WiSE® CRT System across a network of 66 hospitals ⚕️ Supports more efficient procurement and broader hospital access as EBR’s U.S. commercial rollout continues "We are pleased to establish a purchasing agreement with CHRISTUS Health, an organization recognized for its commitment to patient-centered care. This agreement helps broaden institutional access to the WiSE CRT System and supports our ongoing efforts to bring leadless CRT therapy to more patients across the U.S.” John McCutcheon, EBR Systems’ President & CEO ASX announcement ⚡ cdn-api.markitdigital.com/apiman-gateway… @EBRSystemsInc $EBR

49 Metals (ASX:49M) has strengthened its Gold Mountain Project in Nevada with the addition of 8 patented mining claims, enhancing exploration potential and operational flexibility across the highly prospective gold-silver district. ⚒️ Claims added at nil additional consideration under the existing earn-in agreement 🪓 Expanded land position improves access, tenure continuity and future development optionality 🔎 New claims cover historical drilling and high-grade rock chip results warranting follow-up exploration 🛘 Historical rock chip sampling returned grades up to 49.9g/t Au and 1,005g/t Ag ASX announcement ⚡ cdn-api.markitdigital.com/apiman-gateway… @49Metals #49M